Spero Therapeutics (SPRO) Other Non-Current Liabilities (2016 - 2022)
Spero Therapeutics' (SPRO) quarterly Other Non-Current Liabilities came in at $1.0 million in Q1 2022, up 24.69% on a QoQ basis from $802000.0 in Q4 2021.
Spero Therapeutics (SPRO) Other Non-Current Liabilities (2016 - 2022) Analysis & Trends
Spero Therapeutics (SPRO) has 7 years of Other Non-Current Liabilities data on file, last reported at $1.0 million in Q1 2022.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $1.0 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $1.0 million (changed N/A YoY) and the FY2021 annual result came in at $802000.0, changed N/A from the prior year.
- Other Non-Current Liabilities improved to $1.0 million in Q1 2022, from $802000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.0 million in Q1 2022 to a low of $200000.0 in Q3 2018.
- A 5-year average of $347100.0 and a median of $211500.0 in 2018 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2018 — Other Non-Current Liabilities increased 11.5% — and 2019, when it dropped 10.31%.
- Tracing SPRO's Other Non-Current Liabilities over 5 years: stood at $223000.0 in 2018, then slipped by 10.31% to $200000.0 in 2019, then changed by 0.0% to $200000.0 in 2020, then soared by 301.0% to $802000.0 in 2021, then increased by 24.69% to $1.0 million in 2022.
- The last three Other Non-Current Liabilities figures came in at $1.0 million (Q1 2022), $802000.0 (Q4 2021), and $200000.0 (Q1 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 1.00 Mn |
| Dec 31, 2021 | 802,000.00 |
| Mar 31, 2020 | 200,000.00 |
| Sep 30, 2019 | 200,000.00 |
| Jun 30, 2019 | 200,000.00 |
| Mar 31, 2019 | 200,000.00 |
| Dec 31, 2018 | 223,000.00 |
| Sep 30, 2018 | 200,000.00 |
| Jun 30, 2018 | 223,000.00 |
| Mar 31, 2018 | 223,000.00 |
| Dec 31, 2017 | 200,000.00 |
| Sep 30, 2017 | 217,000.00 |
| Jun 30, 2017 | 200,000.00 |
| Dec 31, 2016 | 902,000.00 |
| Sep 30, 2016 | 1.81 Mn |